Navigation Links
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Date:12/19/2007

treatment arm, and none have been reported during the treatment

extension.

* Twenty-four out of 26 patients demonstrated an increase in a-GAL as

measured in white blood cells, kidney, and skin.

* a-GAL increases were seen in patients with both low levels of residual

enzyme activity (<3%) at baseline as well as patients presenting with

higher baseline levels (greater than or equal to 3%).

* Kidney GL-3 levels as measured in urine or biopsies were decreased in

patients who demonstrated greater increases in levels of a-GAL.

* Renal and cardiac function results were encouraging, including those

seen in patients treated for nearly two years.

* Patient responses were consistent with the results of in vitro testing

of Fabry mutations, thus improving the ability to select likely

responders for future studies.

"These data demonstrate that Amigal has a meaningful effect on a range of genetic mutations in Fabry disease and thus has the potential to treat a significant portion of the Fabry patient population," said William Wilcox, M.D., Ph.D., Director of the Metabolic Disorders Clinic at Cedars-Sinai Medical Center and a principal investigator in one of the Amigal clinical trials.

Amicus expects that the results will be presented again at the American College of Medical Genetics (ACMG) Annual Meeting on March 12-16, 2008, in Phoenix, Arizona.

Based on the results of these Phase 2 trials, Amicus and Shire plan to meet with US and European regulatory authorities to discuss the design of a Phase 3 clinical trial for Amigal.

About Fabry Disease

Fabry disease is a lysosomal storage disorder caused by inherited genetic mutations in the GLA gene, which result in deficient activity of the enzyme alpha-galactosidase A (a-GAL). Deficient a-GAL activity leads to lysosomal accumulation of globotriaosylceramide (GL-3), which is believed to cause the various s
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... (PRWEB) January 23, 2015 Biofertilizers stimulate ... such as nitrogen and phosphorous through the activities in ... biofertilizers is increasing due to the stress on reducing ... fertilizers. , The report defines and segments the bio ...
(Date:1/23/2015)... 23, 2015 Portal Solutions , a ... on Microsoft Office 365 and SharePoint platforms , today ... program for being one of the region’s fastest-growing mid-sized companies ... growth. , “To be recognized a second year in ...
(Date:1/22/2015)... Md. (PRWEB) January 22, 2015 ... its new UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength ... high-quality instrument is ideal for applications in a ... life science. , The user-friendly UV-1280 enables intuitive ...
(Date:1/22/2015)... Bedford, NH (PRWEB) January 22, 2015 ... offers a table top laboratory homogenizer, the PandaPLUS 2000, ... nanoparticles, nanodispersions, nanoemulsions , and cell disruption . ... processing dairy products, fruit juices, liquid food, food additives ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2
... ... In the India, CJP is all set to hold 5 Days ... The JatrophaWorld Training Programme 2010-- the Most Authoritative platform shall introduce ... and application technologies, including utilization of Jatropha Crude Oil and Seedcake; ...
... Calif. , May 24 Epeius Biotechnologies Corporation ... study entitled "A Phase I/II Study of Intravenous Rexin-G and ... Annual Meeting on June 6, 2010 . The presentation ... Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, ...
... BEIJING , May 24 /PRNewswire-Asia-FirstCall/ -- Dehaier ... assembly, marketing and,sale of medical products in China , announced today ... . Dehaier,is authorized to distribute all models of this product. , ... HEYER Cumulus ...
Cached Biology Technology:JatrophaWorld Training Programme Slated for India September 20-24, 2010 2JatrophaWorld Training Programme Slated for India September 20-24, 2010 3JatrophaWorld Training Programme Slated for India September 20-24, 2010 4Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010) 2Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010) 3Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China 2Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China 3Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China 4
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES debut of ... Robbins will be at the NXT-ID booth January 6th ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... The North American perimeter security market is ... to 2019. Although the U.S. market holds a larger share ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... It is the first time that a clear link has ... at birth and risk of Autism Spectrum Disorder and follows ... in Sweden. , The research, led by The University of ... poorly grown, low weight babies appear more susceptible to the ...
... 2013 -- A test that measures the expression levels ... effectively differentiate between patients who are at higher and ... the body more than five years after diagnosis, researchers ... individual risk prediction for women with these cancers is ...
... BE, 2 May 2013 -- An important new study ... much measurement variation influences gene expression profiles of breast ... which gene expression measurements may benefit from pooling of ... 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. ...
Cached Biology News:Bigger birth weight babies at greater risk of autism 2Gene expression test distinguishes btw breast cancer patients at high & low risk of late recurrence 2Gene expression test distinguishes btw breast cancer patients at high & low risk of late recurrence 3Study reveals magnitude of variation in gene expression measurements within breast cancers 2Study reveals magnitude of variation in gene expression measurements within breast cancers 3
...
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
...
... atoms at the 3, 3', 4, and ... as an internal standard for the quantification ... PGE1 is the theoretical cyclooxygenase metabolite of ... undetectable in the plasma of normal humans ...
Biology Products: